Cappellini MD, Cohen A, Porter J. Guidelines for the management of transfusion-dependent thalassemia (TDT). Thalassemia International Federation 2021; 4: 1-351.

De Sanctis V, Elsedfy H, Soliman AT. Clinical and biochemical data of adult thalassemia major patients with multiple endocrine complications. Mediterr J Hematol Infect Dis 2022; 8: 2016022. DOI: https://doi.org/10.4084/mjhid.2016.022

Borgna-Pignatti C, Gamberini MR. Complications of thalassemia major and their treatment. Expert Rev Hematol 2023; 4: 353-66. DOI: https://doi.org/10.1586/ehm.11.29

Soliman AT, De Sanctis V, Yassin M. Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia studies. Acta Biomed 2021; 89: 146-55.

Merchant R, Joshi A, Ahmed J. Evaluation of endocrine abnormalities in thalassemia major patients with iron overload. Indian J Pediatr 2021; 78: 679-83. DOI: https://doi.org/10.1007/s12098-010-0351-3

Pepe A, Meloni A, Rossi G. Cardiac complications and diabetes in thalassemia major: a large historical multicentre study. Br J Haematol 2022; 163: 520-7. DOI: https://doi.org/10.1111/bjh.12557

De Sanctis V, Soliman AT, Candini G. High prevalence of endocrine complications in patients with thalassemia major: a long-term follow-up study. Panminerva Med 2021; 55: 85-9.

Shamshirsaz AA, Bekheirnia MR, Kamgar M. Metabolic and endocrinologic complications in beta-thalassemia major: A multicenter study in Tehran. BMC Endocr Disord 2023; 3: 4. DOI: https://doi.org/10.1186/1472-6823-3-4

Casale M, Citarella S, Filosa A. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major. Am J Hematol 2024; 89: 1102-6. DOI: https://doi.org/10.1002/ajh.23844

Toumba M., Sergis A., Kanaris C. Endocrine complications in patients with Thalassemia Major. Pediatric Endocrinology Reviews: PER. 5: 642-648.

Sharma S, Dutt N, Sidhu M. Prevalence of hypothyroidism, diabetes mellitus, and delayed puberty in patients of thalassemia major in a tertiary care center of Jammu province, Jammu & Kashmir, India. Int J Adv Med 2019; 6: 271-4.

E, Neumayr L, Trimble S, Giardina PJ. CDC Thalassemia Investigators. Transfusion complications in thalassemia patients: A report from the Centers for Disease Control and Prevention (CME). Transfusion 2014; 54: 972-81. DOI: https://doi.org/10.1111/trf.12348

Dhouib NG, Ben Khaled M, Ouederni M, Besbes H, Kouki R, Mellouli F, et al. Growth and endocrine function in Tunisian thalassemia major patients. Mediterr J Hematol Infect Dis 2018; 10: 2018031. DOI: https://doi.org/10.4084/mjhid.2018.031

Soliman AT, El Banna N, Abdel Fattah M. Bone mineral density in prepubertal children with beta-thalassemia: correlation with growth and hormonal data. Metabolism. 1998; 47: 541-8. DOI: https://doi.org/10.1016/S0026-0495(98)90237-2

Thuret I, Pondarré C, Loundou A, Steschenko D, Girot R, Bachir D, et al. Complications and treatment of patients with β-thalassemia in France: results of the National Registry. Haematologica 2010; 95: 724-9. DOI: https://doi.org/10.3324/haematol.2009.018051

Hashemizadeh H, Noori R, Kolagari Sh. Assessment Hepatomegaly and liver Enzymes in 100 Patients with beta Thalassemia Major in Mashhad. Iran. Iran J Ped Hematol Oncol 2012; 171-7.

Agarwal MB, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N, et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion-dependent thalassemia: Indian trial. Br J Haematol. 1992; 82: 460-6. DOI: https://doi.org/10.1111/j.1365-2141.1992.tb06445.x

Chirico V, Rigoli L, Lacquaniti A, Salpietro V, Piraino B, Amorini M, et al. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment. Eur J Haematol 2015; 94: 404-12. DOI: https://doi.org/10.1111/ejh.12444

Zervas A, Katopodi A, Protonotariou A, Livadas S, Karagiorga M, Politis C, et al. Assessment of thyroid function in two hundred patients with beta-thalassemia major. Thyroid 2002; 12: 151-4. DOI: https://doi.org/10.1089/105072502753522383

Christoforidis A, Haritandi A, Tsatra I. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with β-thalassemia major: comparison between different chelation regimens. Eur J Haematol 2007; 78: 52-7. DOI: https://doi.org/10.1111/j.0902-4441.2006.t01-1-EJH3013.x

Eshragi P, Tamaddoni A, Zarifi K. Thyroid function in major thalassemia patients: Is it related to height and chelation therapy? Caspian J Intern Med 2011; 2: 189-93.

Cappellini MD, Cohen A, Porter J. Guidelines for the management of transfusion-dependent thalassemia (TDT. Nicosia, Cyprus: Thalassemia International Federation 2014.

Mishra AK, Tiwari A. Iron overload in Beta thalassemia major and intermedia patients. Maedica (Bucur) 2013; 8(4): 328-32.